The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Open accessPublished version of a preprint
Abstract
The off-target distribution of anticancer nanoparticles to fibroblasts creates a barrier to the effective treatment of desmoplastic tumors. However, we hypothesized that this nanoparticle detriment might be exploited to target the expression of secreted cytotoxic proteins from tumor-associated fibroblasts (TAF) as an anticancer strategy. In addressing this hypothesis, plasmids encoding the secretable TNF-related factor sTRAIL were loaded into lipid-coated protamine DNA complexes and administered by infusion in a murine xenograft model of human desmoplastic bladder carcinoma. Three doses were sufficient to generate approximately 70% of TAFs as sTRAIL-producing cells. sTRAIL triggered apoptosis in tumor cell nests adjacent to TAFs. Furthermore, it reverted residual fibroblasts to a quiescent state due to insufficient activation, further compromising tumor growth and remodeling the microenvironment to favor second-wave nanotherapy. We confirmed the efficacy of this strategy in an orthotopic xenograft model of human pancreatic cancer, where the desmoplastic stroma is well known to be a major barrier to the delivery of therapeutic nanoparticles. Collectively, our results offer a proof of concept for the use of nanoparticles to modify TAFs as an effective strategy to treat desmoplastic cancers. Cancer Res; 77(3); 719–31. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus the use of NP to modify CAFs can be an effective strategy to treat desmoplastic cancers (Fig. 2b) [83].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 3×
“Secondly, the reduction of the fibrotic content, which decompresses the intratumoral vasculature, creates a window for the second-wave nanotherapy (9,34).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,740
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,584
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Cited by
Sorted by citations
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,929
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“2b) [83] .”
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Narayanan, J., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,132
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Self-citationFibrosis and cancer: A strained relationship
Piersma, B., Hayward, M.-K., & Weaver, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188356 · Cited by 715
Fiori, M. E., Franco, S. D., Villanova, L., Bianca, P., Stassi, G., & Maria, R. D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 661
Fibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 505
Overchuk, M., & Zheng, G. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 385
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies
Liu, M., Abad, B. L. D. J., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.021 · Cited by 370
Han, X., Li, Y., Xu, Y., Zhao, X., Zhang, Y., Yang, X., Wang, Y., Zhao, R., Anderson, G. J., Zhao, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05906-x · Cited by 339
Self-citationPhuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 285
Self-citationHuang, K., Hsu, F., Qiu, J. T., Chern, G., Lee, Y.-A., Chang, C., Huang, Y., Sung, Y., Chiang, C.-C., Huang, R.-L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5032 · Cited by 262
Self-citationNanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256
He, J., Li, C., Ding, L., Huang, Y., Yin, X., Zhang, J., Zhang, J., Yao, C., Liang, M., Pirraco, R. P., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902409 · Cited by 248
Self-citationNanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 240
Self-citationCancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 262
Recent advances in active targeting of nanomaterials for anticancer drug delivery
Dutta, B., Barick, K. C., & Hassan, P. A. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2021.102509 · Cited by 236
Hyperthermia and smart drug delivery systems for solid tumor therapy
Seynhaeve, A. L. B., Amin, M., Haemmerich, D., van Rhoon, G. C., & ten Hagen, T. L. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.004 · Cited by 239
Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics
Chen, Q., Liu, G., Liu, S., Su, H., Wang, Y., Li, J., & Luo, C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.009 · Cited by 228
Self-citationZhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213
Cancer-associated fibroblasts—heroes or villains?
Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0509-3 · Cited by 216
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P. B., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 210
Applications and challenges of ultra-small particle size nanoparticles in tumor therapy
Xu, J., Song, M., Zhou, F., Zheng, L., Huang, X., & Liu, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.028 · Cited by 188
Liu, Q., Chen, F., Hou, L., Shen, L., Zhang, X., Wang, D., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b01890 · Cited by 182
Self-citationNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Self-citationDesign of nanocarriers based on complex biological barriers in vivo for tumor therapy
Liu, J., Li, M., Luo, Z. Y., Dai, L., Guo, X., & Cai, K. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.010 · Cited by 158
Hou, L., Chen, D., Wang, R., Wang, R., Zhang, H., Zhang, Z., Nie, Z., & Lu, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202014397 · Cited by 144
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 139
Self-citationShen, L., Li, J., Liu, Q., Song, W., Zhang, X., Tiruthani, K., Hu, H., Das, M., Goodwin, T. J., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00967 · Cited by 139
Self-citationMartin, J. D., Panagi, M., Wang, C., Khan, T., Martin, M. R., Voutouri, C., Toh, K., Papageorgis, P., Mpekris, F., Polydorou, C., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b07865 · Cited by 138
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 132
Self-citationChan, T., Shaked, Y., & Tsai, K. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00688 · Cited by 124
Yu, Q., Qiu, Y., Li, J., Tang, X., Wang, X., Cun, X., Xu, S., Liu, Y., Li, M., Zhang, Z., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.040 · Cited by 118
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
Gowd, V., Ahmad, A., Tarique, M., Suhail, M., Zughaibi, T. A., Tabrez, S. S. M., & Khan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.026 · Cited by 115
Ni, K., Xu, Z., Culbert, A. A., Luo, T., Guo, N., Yang, K., Pearson, E. A., Preusser, B., Wu, T., Rivière, P. J. L., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00846-w · Cited by 117
Feng, J., Xu, M., Wang, J., Zhou, S., Liu, Y., Liu, S., Huang, Y., Chen, Y., Liang, C., Song, Q., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119907 · Cited by 108
Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines
Li, M., Zhang, Y., Zhang, Q., & Li, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100364 · Cited by 111
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Jing, Z., Du, Q., Zhang, X., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137147 · Cited by 108
Liu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 103
Das, M., Shen, L., Liu, Q., Goodwin, T. J., & Huang, L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.012 · Cited by 95
Self-citationNanoparticles mediated tumor microenvironment modulation: current advances and applications
Raju, G. S. R., Pavitra, E., Varaprasad, G. L., Bandaru, S. S., Nagaraju, G. P., Farran, B., Huh, Y. S., & Han, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01476-9 · Cited by 101
Truffi, M., Mazzucchelli, S., Bonizzi, A., Sorrentino, L., Allevi, R., Vanna, R., Morasso, C., & Corsi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061263 · Cited by 93
Hou, L., Liu, Q., Shen, L., Liu, Y., Zhang, X., Chen, F., & Huang, L. (2018) · Theranostics · doi:10.7150/thno.24821 · Cited by 90
Self-citationPei, Y., Liang, C., Huang, Y., Wang, J., Feng, J., Xu, M., Chen, Y., Song, Q., Jiang, G., Gu, X. Q., et al. (2019) · Small · doi:10.1002/smll.201900631 · Cited by 91
Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
Sun, B., Hyun, H., Li, L., & Wang, A. Z. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0424-4 · Cited by 91
Guo, J. X., Zeng, H., & Chen, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00014 · Cited by 91
Yu, Q., Tang, X., Zhao, W., Qiu, Y., He, J., Wan, D., Li, J., Wang, X., He, X., Liu, Y., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.002 · Cited by 86
Liu, Q., Zhu, H., Tiruthani, K., Shen, L., Chen, F., Gao, K., Zhang, X., Hou, L., Wang, D., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07384 · Cited by 83
Self-citationLiu, Y., Tiruthani, K., Wang, M., Zhou, X., Qiu, N., Xiong, Y., Pecot, C. V., Liu, R., & Huang, L. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00588f · Cited by 81
Self-citationDrug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
Liu, M., Song, W., & Huang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.032 · Cited by 83
Self-citationmRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85
Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors
Chen, Y., Song, W., Shen, L., Qiu, N., Hu, M., Liu, Y., Liu, Q., & Huang, L. (2019) · ACS Nano · doi:10.1021/acsnano.8b07830 · Cited by 81
Self-citationApplication of nanotechnology in the diagnosis and treatment of bladder cancer
Xu, Y., Luo, C., Wang, J., Chen, L., Chen, J., Chen, T., & Zeng, Q. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01104-y · Cited by 78
Self-citationLiu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 78
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 77
Complex interplay between tumor microenvironment and cancer therapy
Shen, M., & Kang, Y. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0663-7 · Cited by 76
Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 79
Stromal reprogramming: A target for tumor therapy
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117049 · Cited by 74
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
Spano, C., Grisendi, G., Golinelli, G., Rossignoli, F., Prapa, M., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., Miselli, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37433-6 · Cited by 76
Amini, M. A., Abbasi, A. Z., Cai, P., Lip, H., Gordijo, C. R., Li, J., Chen, B., Zhang, L., Rauth, A. M., & Wu, X. Y. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy131 · Cited by 72
Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Raaijmakers, K., Adema, G. J., Bussink, J., & Ansems, M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03251-0 · Cited by 78
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 74
TRAIL-based gene delivery and therapeutic strategies
Zhong, H., Wang, H., Li, J., & Huang, Y. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0287-8 · Cited by 74
TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies
Dianat‐Moghadam, H., Heidarifard, M., Mahari, A., Shahgolzari, M., Keshavarz, M., Nouri, M., & Amoozgar, Z. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104716 · Cited by 70
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
Zhao, Z., Li, T., Sun, L. L., Yuan, Y., & Zhu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115425 · Cited by 71
Hameed, S., Chen, H., Irfan, M. I., Bajwa, S. Z., Khan, W. S., Baig, S. M., & Dai, Z. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00812 · Cited by 65
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 65
Mortezaee, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117145 · Cited by 63
Multifunctional nanostructures: Intelligent design to overcome biological barriers
Azizi, M., Jahanban‐Esfahlan, R., Samadian, H., Hamidi, M., Seidi, K., Dolatshahi‐Pirouz, A., Ahmadieh-Yazdi, A., Shavandi, A., Laurent, S., Hagh, M. B. O., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100672 · Cited by 63
Yu, S., Wang, S., Wang, X., & Xu, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03518-8 · Cited by 70
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 62
BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma
Liu, Q., Zhu, H., Liu, Y., Musetti, S., & Huang, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2079-7 · Cited by 62
Self-citationNanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer
Liu, Y., Qiu, N., Shen, L., Liu, Q., Zhang, J., Cheng, Y., Lee, K., & Huang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.040 · Cited by 64
Self-citationStrategies targeting tumor immune and stromal microenvironment and their clinical relevance
Hu, M., & Huang, L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114137 · Cited by 60
Self-citationFor and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy
Karimi, S., Bakhshali, R., Bolandi, S., Zahed, Z., Zadeh, S. S. M., Zenjanab, M. K., & Jahanban‐Esfahlan, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101626 · Cited by 60
Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 59
Tanaka, H., Sakurai, Y., Anindita, J., & Akita, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.001 · Cited by 56
TRAIL–NP hybrids for cancer therapy: a review
Belkahla, H., Herlem, G., Picaud, F., Gharbi, T., Hémadi, M., Ammar, S., & Micheau, O. (2017) · Nanoscale · doi:10.1039/c7nr01469d · Cited by 53
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
Caster, J. M., Callaghan, C. M., Seyedin, S. N., Henderson, K., Sun, B., & Wang, A. Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.009 · Cited by 56
Responsive and activable nanomedicines for remodeling the tumor microenvironment
Zhang, Y., Han, X., & Nie, G. (2020) · Nature Protocols · doi:10.1038/s41596-020-00421-0 · Cited by 51
Extracellular citrate and metabolic adaptations of cancer cells
Parkinson, E. K., Adamski, J., Zahn, G., Gaumann, A. K. A., Flores‐Borja, F., Ziegler, C. M., & Mycielska, M. E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10007-1 · Cited by 50
Huang, H., Sung, Y., Li, C., Wan, D., Chao, P., Tseng, Y., Liao, B.-W., Cheng, H., Hsu, F., Huang, C., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325180 · Cited by 51
Liu, C., Chern, G., Hsu, F., Huang, K., Sung, Y., Huang, H., Qiu, J.-T. T., Wang, S., Lin, C., Wu, C., et al. (2017) · Hepatology · doi:10.1002/hep.29513 · Cited by 51
Self-citationChen, X., Yu, Q., Liu, Y., Sheng, Q., Shi, K., Wang, Y., Li, M., Zhang, Z., & He, Q. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.003 · Cited by 51
Self-citationNanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy
Wu, X., Wang, S., Li, M., Wang, A., Zhou, Y. Y., Li, P., & Wang, Y. (2017) · Nanoscale · doi:10.1039/c7nr04959e · Cited by 50
Self-citationNormalization in tumor ecosystem: Opportunities and challenges
Mortezaee, K. (2021) · Cell Biology International · doi:10.1002/cbin.11655 · Cited by 49
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine
Cassani, M., Fernandes, S., Pagliari, S., Cavalieri, F., Caruso, F., & Forte, G. (2025) · Advanced Science · doi:10.1002/advs.202409898 · Cited by 48
Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues
Elwakeel, E., & Weigert, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111636 · Cited by 49
Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
Sakurai, Y., Abe, N., Yoshikawa, K., Oyama, R., Ogasawara, S., Murata, T., Nakai, Y., Tange, K., Tanaka, H., & Akita, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.052 · Cited by 46
Li, W., Little, N., Park, J., Foster, C. A., Chen, J., & Lu, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00455 · Cited by 46
Dana, P., Thumrongsiri, N., Tanyapanyachon, P., Chonniyom, W., Punnakitikashem, P., & Saengkrit, N. (2022) · Nanomaterials · doi:10.3390/nano13010107 · Cited by 44
Recent advances in drug delivery and targeting for the treatment of pancreatic cancer
Pramanik, N., Gupta, A. K., Ghanwatkar, Y., & Mahato, R. I. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.053 · Cited by 42
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 44
Drug Delivery Strategies for the Treatment of Pancreatic Cancer
Olajubutu, O., Ogundipe, O. D., Adebayo, A. S., & Adesina, S. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051318 · Cited by 46
Liu, X., Zhou, J., Wu, H., Chen, S., Zhang, L., Tang, W., Duan, L., Wang, Y., McCabe, E., Hu, M., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.012 · Cited by 41
Self-citationPolymer-Mediated Penetration-Independent Cancer Therapy
Ding, J., Feng, X., Jiang, Z., Xu, W., Guo, H., Zhuang, X., & Chen, X. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01263 · Cited by 41
Metadata
- Authors
- Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Shenyang Pharmaceutical University (CN)
- China Pharmaceutical University (CN)
- Corresponding author
- Huang, Leaf
- ORCID
- Venue
- Cancer Research
- Published
- 2017-01-31
- Volume
- 77
- Issue
- 3
- Pages
- 719-731
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC5290135
- OpenAlex
- W2555883270
- Cited by
- 215
- References
- 50
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 16 · 2023: 16 · 2022: 26 · 2021: 29 · 2020: 31 · 2019: 31 · 2018: 21 · 2017: 16
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- NIH (CA149363, CA151652, and CA149387)
- North Carolina Biotech Center Institutional (2005-IDG-1016)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- cancer-associated fibroblasts, desmoplastic tumors, tumor microenvironment, lipid-coated nanoparticles, pancreatic cancer, nanoparticle delivery
- MeSH terms
- Cancer-Associated Fibroblasts, Animals, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Flow Cytometry, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Neoplasms, Experimental, Pancreatic Neoplasms, Blotting, Western, Polymerase Chain Reaction, Apoptosis, Xenograft Model Antitumor Assays, NIH 3T3 Cells, Cell Line, Tumor, Mice, TNF-Related Apoptosis-Inducing Ligand, Nanoconjugates, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
